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Breast cancer is the most common and the leading cause of
mortality in women worldwide. There is a dire necessity of the
identiﬁcation of novel molecules useful in diagnosis and prognosis.
In this work we determined the differentially expression proﬁles of
four breast cancer cell lines compared to a control cell line. We
identiﬁed 1020 polypeptides labelled with iTRAQ with more than
95% in conﬁdence. We analysed the common proteins in all breast
cancer cell lines through IPA software (IPA core and Biomarkers). In
addition, we selected the speciﬁc overexpressed and subexpressed
proteins of the different molecular classes of breast cancer cell lines,
and classiﬁed them according to protein class and biological
process. Data in this article is related to the research article
“Determination of the protein expression proﬁles of breast cancer
cell lines by Quantitative Proteomics using iTRAQ Labelling and
Tandem Mass Spectrometry” (Calderón-González et al. [1] in press).
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableSubject area Cell Biology
More speciﬁc
subject areaBreast cancerType of data Tables, ﬁgures
How data was
acquiredIsobaric labelling, preparative isoelectrofocusing, reverse phase chromatography and tandem mass
spectrometry using an AB SCIEX high performance hybrid quadrupole time-of-ﬂight QSTAR ESI XL
Hybrid LC/MS/MS Mass Spectrometer SystemData format Analysed and ﬁltered
Experimental factors Samples were reduced with 50 mM TCEP, alkylated with 200 mM MMTS, digested with sequencing
grade trypsin and labelled according to the manufacturer's protocol of iTRAQ 8-plex kit, with minor
modiﬁcationsExperimental
featuresAn amount of 110 μg of total protein from each normal and breast cancer cell line were trypsin-
digested, iTRAQ-labelled and pooled. Labelled-peptides were separated by isoelectrofocusing on a
non-linear pH 3–10 gradient. Strips were divided in sections and peptides extracted and
chromatographed in a C18 reverse phase column. Elution was done using several linear gradients of
ACN and eluted peptides were analysed in a QSTAR ESI XL Hybrid LC/MS/MS Mass Spectrometer
System. Collected mass spectra were analysed with the 4.0 ProteinPilot program and a cut-off of 20%
fold change in the relative quantitation ratio was set. Identiﬁed proteins were grouped and classiﬁed
with PANTHER (v 9.0) and IPA softwareData source location Mexico City, Mexico
Data accessibility Data is within this articleValue of the data Differential protein expression proﬁles of breast cancer cell lines.
 Diseases and biofunctions analysis by IPA of over- and subexpressed polypeptides found in
common in all breast cancer cell lines.
 Comparative analysis of putative biomarkers found in common in all breast cancer cell lines.
 Identiﬁcation of speciﬁc over- and subexpressed proteins for each breast cancer cell line.
 Classiﬁcation of speciﬁc proteins in each breast cancer cell lines according to protein class and
biological process with PANTHER.
Fig. 1. IPA functional networks of differentially expressed proteins through different core analyses. There are only shown the
two top networks of each core analysis. Core I networks are related with: (A) Cancer; Reproductive System Diseases;
Dermatological Diseases and Conditions; Haematological Diseases. (B) Connective Tissue Disorders; Neurological Diseases;
Skeletal and Muscular Disorders; DNA replication, Recombination and Repair; Cancer; Gastrointestinal Diseases. Core II
networks are implicated in: (C) Cellular Development; Cellular Growth and Proliferation; Cell Cycle. (D) Cell Death and Survival;
Tumour Morphology; Cellular Development. Core III analysis was performed for proteins involved in: (E) Cell Cycle; Cancer;
Hereditary Disorders; Haematological Diseases. (F) Developmental Disorders, Hereditary Disorders; Metabolic Diseases; Cell
Death and Survival. Different shapes, indicating the functional class to which they belong, represent proteins. Molecules in red
are overexpressed polypeptides, whilst those green molecules correspond to subexpressed proteins. Molecules in grey, which
are not speciﬁed, were incorporated into the networks by IPA through relationships with other molecules. Molecular
relationships between polypeptides are indicated with lines. A continuous line illustrates a direct interaction and a dotted line
is used for indirect interactions.
K.G. Calderón-González et al. / Data in Brief 4 (2015) 292–3012941. Data
We identiﬁed 1020 iTRAQ-labelled proteins with at least one peptide with a minimum of 95% in
conﬁdence with the ProteinPilot software (Table 1).
1.1. IPA analysis of the differentially expressed proteins found in common in all breast cancer cell lines
To determine whether over- or subexpressed polypeptides have been involved in diseases and
biofunctions, or localised in networks, we used the IPA software to perform mainly three different
core analyses: (a) Core I considered all tissues, primary cells and all cell lines. (b) Core II was
performed for breast cancer cell lines and mammary gland. (c) Core III, for all cancer cell lines
excluding breast cancer cell lines (Table 2). They were obtained for different categories of diseases and
biofunctions, using a p-value equal or lower than 0.05, which was obtained with Fisher´s Exact Test.
Core analyses I and III shared similarities in the results obtained. Core I included 78 categories of
diseases and biofunctions, whilst 11 categories were found in Core II and 72 in Core III. The most
representative categories in Core I were Nucleic Acid Metabolism (16 proteins and p-values between
4.461010 and 2.53102), Small Molecule Biochemistry (36 polypeptides and p-values ranging
from 4.461010 to 3.77102), DNA Replication, Recombination and Repair (19 proteins, p-values
Fig. 2. Venn-Euler diagrams of putative biomarkers obtained through IPA and PubMed analyses. Diagrams shows the putative
biomarkers found with IPA Biomarkers ﬁlter I (all tissues, primary cells and all cell lines), II (mammary gland and breast cancer)
and III (cancer cell lines excluding breast cancer cell lines), and those obtained with PubMed database search.
(A) Overexpressed proteins and (B) Subexpressed polypeptides common in all breast cancer cell lines.
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Fig. 3. Venn-Euler diagrams of overexpressed proteins in the different molecular types of breast cancer cell lines. (A) The
diagram shows the speciﬁc proteins in the Luminal A cell lines (MCF7 and T47D) as well as common proteins in these lines.
(B) Diagram shows the unique proteins for Claudin-low (MDA-MB-231) and HER2þ (SK-BR-3) cell lines, and the comparison of
the common proteins in Luminal A cell lines with the other types of cell lines.
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Fig. 4. Venn-Euler diagrams of subexpressed proteins in the different molecular types of breast cancer cell lines. (A) The
diagram shows the speciﬁc proteins in the Luminal A cell lines (MCF7 and T47D) as well as common proteins in these lines.
(B) Diagram show the unique proteins for Claudin low (MDA-MB-231) and HER2þ (SK-BR-3) cell lines, and the comparison of
the common proteins in Luminal A cell lines with the other types of cell lines.
K.G. Calderón-González et al. / Data in Brief 4 (2015) 292–301 297between 7.241010 and 3.77102), and Energy Production (10 polypeptides and a p-values of
7.241010). In Core II we got the following categories: Cellular Response to Therapeutics (only
2 proteins with a p-value of 2103), Cellular Movement (9 polypeptides and p-values from
1.72102 to 3.67102), Cell Morphology and Cellular Assembly and Organisation (2 polypeptides,
p-value of 1.85102). Finally, the most representative categories in Core III were the same as in Core
K.G. Calderón-González et al. / Data in Brief 4 (2015) 292–301298I: Nucleic Acid Metabolism (16 polypeptides, p-values ranging from 4.61010 to 4.02102), Small
Molecule Biochemistry (34 proteins, p-values between 4.61010 and 4.02102), DNA Replication,
Recombination and Repair (21 proteins, p-values from 7.461010 to 3.78102), and Energy
Production (12 proteins, p-values from 7.461010 to 4.02102).
The two top networks obtained in Core I analysis were related with: (1) Cancer; Reproductive
System Disease; Dermatological Diseases and Conditions; Haematological Diseases, which showed a
score of 38 and contained 25 target molecules. (2) Connective Tissue Disorders; Neurological Disease;
Skeletal and Muscular Disorders; DNA Replication, Recombination and Repair; Cancer; Gastro-
intestinal Diseases, that had a score of 27 and a network focused on 20 molecules (Fig. 1A and B). In
Core II analysis, the two most representative networks were involved in: (1) Cellular Development,
Cellular Growth and Proliferation, and Cell Cycle, with a score of 15 and a network of 15 polypeptides.
(2) Cell Death and Survival, Tumour Morphology, and Cellular Development. In this case, the score was
9 and the network generated was focused on 11 molecules (Fig. 1C and D). Finally, the Core III analysis
contained polypeptides playing a role in: (1) Cell Cycle, Cancer, Hereditary Disorders, and
Haematological Diseases. In this case, it showed a score of 41 and considered 26 proteins (Fig. 1E).
(2) Developmental Disorders, Hereditary Disorders, Metabolic Diseases, and Cell Death and Survival.
This network had a score of 24 and contained 18 polypeptides (Fig. 1F).1.2. Selection of putative biomarkers found in common in all breast cancer cell lines
For the identiﬁcation of putative biomarkers we used two different approaches: (1) Filtering
candidate biomarkers with the IPA software, and (2) Searching of proteins in the PubMed database.
The ﬁrst ﬁlter, named Biomarkers I, was carried out in all tissues, primary cells and all cell lines
information contained in the Ingenuity Knowledge database; the second one was through breast
cancer cell lines and mammary gland (Biomarkers II), and the third consisted in ﬁltering through
cancer cell lines, excluding breast cancer cell lines and was named Biomarkers III. Results obtained in
Biomarkers I revealed 39 potential candidates: ACAA2, ACAT1, ANXA2, CAP2, CPT1A, CTNNA1, CTSC,
CYB5R3, DNMT1, EGFR, EIF4B, ETFB, F11R, FLNB, GAPDH, GLUD1, GSTP1, HADHA, HADHB, HLA-A,
HMGB1, HMGB2, HNRNPU, HSP90AA1, IL18, JUP, MCM2, MYH9, NNMT, PEBP1, PHB, SERPINB5, SLC2A1,
SOD2, TOP2A, TPI1, TPM2, TRIM29, XPO1. Biomarkers II included 9 putative targets: CTSC, CYB5R3,
EGFR, EIF4B, FLNB, GSTP1, IL18, MYH9, TOP2A. Finally, Biomarkers III selected 24 polypeptides, which
included ANXA2, CAP2, CTNNA1, DNMT1, EGFR, GAPDH, GLUD1, GSTP1, HLA-A, HMGB1, HSP90AA1,
IL18, JUP, MCM2, NNMT, PHB, SERPINB5, SLC2A1, SOD2, TOP2A, TPI1, TPM2, TRIM29 and XPO1. All of
these potential biomarkers were in common in all studied breast cancer cell lines.
In relation to the search for candidates in the PubMed database, we obtained 35 overexpressed and
53 subexpressed polypeptides not previously reported in breast cancer, with one exception, ANXA8,
which has only one report [2]. Finally, we performed a comparison between the biomarkers found
with IPA and those in the PubMed search. These analyses revealed only 3 speciﬁc overexpressed
polypeptides in Biomarkers I, and 34 in the PubMed search (Fig. 2A). For subexpressed proteins, we
obtained 6 polypeptides for Biomarkers I, and 51 in PubMed (Fig. 2B). Biomarkers II and III modules
did not ﬁnd exclusive markers in both cases.1.3. Panel of putative biomarkers exclusively found in Luminal A, Claudin-low and HER2þ breast cancer
cell lines
We identiﬁed sets of speciﬁc proteins for Luminal A, Claudin-low and HER2þ breast cancer cell
lines. We obtained a set of proteins shared by Luminal A cell lines containing 34 overexpressed
(Fig. 3A) and 22 subexpressed polypeptides (Fig. 4A). In the case of Claudin-low, we identiﬁed a set
with 55 and 44 overexpressed and subexpressed polypeptides, respectively (Figs. 3B and 4B). The
HER2þ cell line showed 74 overexpressed (Fig. 3B) and 49 subexpressed proteins (Fig. 4B). However,
we need to determine the expression levels of these proteins in tumour tissues and or sera to validate
them as biomarkers.
Fig. 5. PANTHER functional classiﬁcation of overexpressed proteins found exclusively in each breast cancer cell line. The graph
shows the number of genes involved in the different Protein Class (A) and Biological Process (B) of the speciﬁc proteins in each
breast cancer cell line. The total numbers of class hits were 54, 77, 84 and 97 for Protein Class and 61, 96, 132, and 127 for
Biological Process in MCF7, T47D, MDA-MB-231 and SK-BR-3 cell lines.
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line
The overexpressed and subexpressed speciﬁc proteins of each breast cancer cell line (MCF7, T47D,
MDA-MB-231, SK-BR-3) were classiﬁed with PANTHER. For Protein Class of overexpressed proteins, we
obtained 26 categories, being the Nucleic Acid Binding (XIV) the most representative category for
MCF7, T47D and MDA-MB-231, and Hydrolase (VIII) and Oxidoreductase (XV) for SK-BR-3 (Fig. 5A). In
the case of the Biological Processes, we found 12 categories, being the Metabolic process (IX) the
category with more genes implicated (Fig. 5B). On the other hand, the categorisation of subexpressed
proteins speciﬁc for each cell line had 25 categories in Protein Class and 12 in Biological Processes. The
categories of Protein Class with mayor number of genes were Hydrolase (VII) for MCF7, and T47D,
Nucleic Acid Binding (XIII) for MDA-MB-231 and SK-BR-3 (Fig. 6A). The category of Biological Process
most affected was Metabolic process (IX) in each of cell line (Fig. 6B).2. Experimental design, materials and methods
2.1. IPA analysis of proteins in common in all breast cancer cell lines
To identify diseases and biological functions, canonical pathways, molecular networks, and putative
candidates for biomarkers from the proteins that are commonly express in all breast cancer cell lines,
we used the complete functional Ingenuity Pathway Analysis software (IPA, QIAGENs Redwood City,
www.qiagen.com/ingenuity). We performed three different analyses named Cores I, II and III. In all cases
Fig. 6. PANTHER functional classiﬁcation of subexpressed proteins found in each breast cancer cell line. The graph shows the
number of genes involved in the different Protein Class (A) and Biological Process (B) of the speciﬁc proteins in each breast
cancer cell line. The total numbers of class hits were 57, 41, 55 and 64 for Protein Class and 72, 52, 70, and 87 for Biological
Process in MCF7, T47D, MDA-MB-231 and SK-BR-3 cell lines.
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considered as signiﬁcant with values r0.05. Core I was done to classify identiﬁed proteins in all tissues,
primary cells and all cell lines including cervical, central nervous system, colon, hepatoma, immune,
kidney, leukaemia, lung, lymphoma, macrophage, melanoma, myeloma, neuroblastoma, osteosarcoma,
ovarian, pancreatic, prostate, teratocarcioma, breast cancer and other cell lines. Core II was used in
mammary gland and breast cancer cell lines. Core III in all cancer cell lines, excluding breast cancer cell
lines. Parameters used in the complete analysis were: (i) ingenuity knowledge base (genes only),
considering direct and indirect relationships. (ii) Interaction networks including endogenous chemicals,
default value of 35 molecules per network and 25 networks per analysis. (iii) All data source. (iv)
Conﬁdence: experimentally observed, highly and moderately predicted. (v) Human species with
stringent ﬁlter. (vi) All mutations.2.2. Selection of putative biomarkers common in all breast cancer cell lines
We used the module IPA biomarker to prioritise protein biomarker candidates in our data. Three
analyses were carried out, Biomarkers I included a ﬁlter for all tissues, primary cells and all cell lines,
Biomarkers II for breast cancer cell lines and mammary gland, and Biomarkers III for cancer cell lines,
excluding breast cancer. Parameters used were: (1) human species. (2) All molecule types. (3) All
bioﬂuids. (4) All diseases for Biomarkers I, and cancer disease for Biomarkers II and III. (5) Biomarkers
I, all biomarkers and disease application. For Biomarkers II, all biomarkers application and breast
cancer disease (including breast cancer, breast carcinoma, ductal carcinoma, ductal carcinoma in situ,
inﬁltrating ductal breast carcinoma, invasive ductal breast cancer, lobular breast carcinoma, and
metastatic breast cancer). In the case of Biomarkers III, all biomarkers application and cancer disease
excluding breast cancer.
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expression levels in common in all breast cancer cell lines in PubMed database using key words such
as biomarkers, cancer and breast cancer. Finally, we performed a comparison analysis of the results
obtained with IPA Biomarker modules and PubMed with the Venny program (developed by Oliveros
JC and available at http://bioinfogp.cnb.csic.es/tools/venny/).
2.3. Selection of biomarkers panel in the different molecular classiﬁcation of breast cancer cell lines
For the selection of the exclusive sets of overexpressed and subexpressed polypeptides for Luminal
A, Claudin-low and HER2þ cell lines, we performed a comparative analysis of between themwith the
Venny program.
2.4. Functional classiﬁcation of the exclusive sets of proteins for each breast cancer cell lines according to
their corresponding molecular classiﬁcation with PANTHER
The speciﬁc sets of polypeptides for each breast cancer cell line according to their corresponding
molecular classiﬁcation were analysed with the PANTHER classiﬁcation system v 9.0 (http://www.
pantherdb.org/) [3]Acknowledgements
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